MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Market Cap
$231.60M
P/E Ratio
-2.35
1Y Stock Return
-56.33%
1Y Revenue Growth
16.68%
Dividend Yield
0.00%
Price to Book
1.9
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Current Value
$3.681 Year Return
Current Value
$3.681 Year Return
Yahoo
ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month: 7th Annual Evercore HealthCONx (Coral Gables, FL). MacroGenics’ President and Chief Executive Officer, Scott Koenig, M.D., Ph
Yahoo
As November 2024 comes to a close, the U.S. stock market is celebrating record highs with the S&P 500 and Dow Jones Industrial Average posting their biggest monthly gains of the year. For investors willing to explore beyond large-cap stocks, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities. Despite being considered a relic by some, these stocks can still provide significant potential when backed by strong financials, making them an...
Yahoo
MacroGenics ( NASDAQ:MGNX ) Third Quarter 2024 Results Key Financial Results Revenue: US$110.7m (up by US$100.3m from...
Yahoo
ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month: Guggenheim Securities Healthcare Innovation Conference (Boston). MacroGenics’ Chief Operating Officer, Eric Risser, will participate in a fi
Yahoo
Q3 2024 MacroGenics Inc Earnings Call
Yahoo
Macrogenics Inc (MGNX) reports a remarkable revenue increase driven by milestone payments, while navigating leadership changes and strategic pauses in development.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FAT | 46.20% | $94.86M | -7.23% | 10.45% |
LAW | 39.32% | $359.45M | -6.10% | 0.00% |
COLL | 38.90% | $1.01B | +19.67% | 0.00% |
AKAM | 38.10% | $14.71B | -15.50% | 0.00% |
OKLO | 34.60% | $2.71B | +114.78% | 0.00% |
SKLZ | 32.74% | $101.68M | -10.24% | 0.00% |
MVIS | 32.64% | $197.49M | -66.73% | 0.00% |
SSP | 32.35% | $175.32M | -74.21% | 0.00% |
ANAB | 32.16% | $741.85M | +56.38% | 0.00% |
XPOF | 32.02% | $500.45M | +8.92% | 0.00% |
FATBB | 31.84% | $78.36M | -13.31% | 12.28% |
RWAY | 30.80% | $394.57M | -15.55% | 15.19% |
BHVN | 30.72% | $4.52B | +31.82% | 0.00% |
AVD | 30.69% | $176.47M | -38.88% | 1.47% |
ZYME | 30.12% | $1.01B | +57.10% | 0.00% |
GRAL | 30.03% | $629.34M | +10.18% | 0.00% |
EGAN | 29.36% | $164.01M | -28.13% | 0.00% |
FROG | 29.35% | $3.44B | +9.18% | 0.00% |
FLUX | 27.14% | $30.36M | -46.78% | 0.00% |
ALDX | 26.95% | $287.03M | +47.40% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -16.09% | $365.42M | 1.43% |
DBA | -12.29% | $787.55M | 0.93% |
TPMN | -10.20% | $40.42M | 0.65% |
VIXY | -9.37% | $195.31M | 0.85% |
CTA | -9.03% | $367.83M | 0.76% |
USDU | -8.68% | $210.52M | 0.5% |
UUP | -7.79% | $376.91M | 0.77% |
GSG | -7.75% | $932.06M | 0.75% |
WEAT | -7.51% | $119.27M | 0.28% |
PDBC | -7.50% | $4.39B | 0.59% |
HIGH | -7.46% | $302.94M | 0.52% |
DBO | -7.41% | $218.47M | 0.77% |
FTGC | -7.41% | $2.20B | 1.02% |
BCI | -7.20% | $1.21B | 0.26% |
COMT | -7.09% | $839.86M | 0.48% |
DBE | -7.03% | $50.22M | 0.77% |
CMDY | -6.99% | $284.26M | 0.28% |
BCD | -6.96% | $243.18M | 0.3% |
EQLS | -6.96% | $8.93M | 1% |
GCC | -6.81% | $136.27M | 0.55% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NVAX | -24.69% | $1.40B | +52.52% | 0.00% |
ITOS | -24.12% | $312.36M | -15.35% | 0.00% |
MTD | -22.42% | $26.57B | +14.15% | 0.00% |
NNI | -22.16% | $3.99B | +28.65% | 1.01% |
GEN | -20.74% | $19.06B | +37.59% | 1.62% |
ORGO | -17.62% | $511.75M | +40.88% | 0.00% |
ADMA | -16.79% | $4.65B | +407.47% | 0.00% |
OBDE | -14.92% | $1.84B | -0.81% | 4.70% |
PSN | -14.22% | $10.19B | +48.51% | 0.00% |
GAN | -14.17% | $82.94M | +21.33% | 0.00% |
PGR | -13.74% | $154.68B | +61.58% | 0.43% |
IAG | -13.18% | $3.10B | +115.48% | 0.00% |
WLKP | -12.99% | $840.09M | +8.96% | 7.91% |
INSG | -12.36% | $183.80M | +395.96% | 0.00% |
SG | -12.36% | $4.54B | +293.88% | 0.00% |
HRB | -12.21% | $8.10B | +27.36% | 2.26% |
GRVY | -12.05% | $466.34M | -9.54% | 0.00% |
CTLP | -12.04% | $667.82M | +25.51% | 0.00% |
COR | -11.07% | $48.29B | +22.63% | 0.82% |
ACIC | -10.86% | $648.84M | +55.79% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
EWH | -0.05% | $644.15M | 0.5% |
FLTR | -0.06% | $1.83B | 0.14% |
FTXN | -0.10% | $172.28M | 0.6% |
DBMF | 0.14% | $1.04B | 0.85% |
CLOI | 0.18% | $749.05M | 0.4% |
URA | 0.23% | $3.83B | 0.69% |
FMF | -0.36% | $248.49M | 0.95% |
TBIL | 0.53% | $4.42B | 0.15% |
BILZ | -0.57% | $541.42M | 0.14% |
DUSB | 0.58% | $828.65M | 0.15% |
COPX | -0.59% | $2.64B | 0.65% |
EWJV | 0.61% | $258.90M | 0.15% |
AMDY | -0.63% | $148.59M | 0.99% |
RSPG | 0.63% | $550.39M | 0.4% |
JUCY | -0.64% | $325.86M | 0.6% |
IGE | 0.70% | $646.72M | 0.41% |
TBLL | 0.94% | $1.94B | 0.08% |
PICK | 0.95% | $866.75M | 0.39% |
IEO | 0.97% | $648.93M | 0.4% |
PXJ | 1.03% | $43.97M | 0.66% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
OPTN | 0.02% | $81.15M | -63.15% | 0.00% |
LBRDA | -0.02% | $12.03B | +1.45% | 0.00% |
MFC | 0.03% | $56.62B | +62.90% | 3.60% |
MFIC | 0.04% | - | - | 10.72% |
CRNT | -0.05% | $357.22M | +123.06% | 0.00% |
OCSL | 0.06% | - | - | 13.36% |
ARLP | 0.07% | $3.56B | +33.14% | 10.11% |
GIS | -0.07% | $37.20B | +3.17% | 3.55% |
LMB | 0.07% | $1.16B | +153.14% | 0.00% |
NINE | 0.07% | $71.17M | -24.32% | 0.00% |
NEXA | -0.08% | $1.01B | +30.86% | 0.00% |
NAT | 0.08% | $551.22M | -33.83% | 15.82% |
GRFS | 0.09% | $1.84B | -26.57% | 0.00% |
CREG | 0.09% | $6.32M | -35.67% | 0.00% |
HCA | -0.11% | $82.99B | +27.41% | 0.78% |
VET | 0.12% | $1.57B | -15.57% | 3.32% |
VLRS | 0.13% | $883.98M | -4.12% | 0.00% |
GPRK | 0.13% | $532.60M | +17.10% | 5.17% |
AIFU | -0.14% | $72.59M | -80.19% | 0.00% |
KSPI | -0.17% | $20.17B | +10.59% | 3.50% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 31.67% | $7.29B | 0.35% |
XPH | 28.62% | $164.49M | 0.35% |
ARKG | 28.32% | $1.27B | 0.75% |
GNOM | 28.17% | $79.38M | 0.5% |
IBB | 27.15% | $6.97B | 0.45% |
PBE | 26.81% | $263.25M | 0.58% |
IHE | 26.10% | $612.43M | 0.39% |
RSPA | 25.77% | $278.68M | 0% |
IWC | 25.61% | $996.57M | 0.6% |
BBH | 24.79% | $421.45M | 0.35% |
IWO | 24.38% | $13.37B | 0.24% |
XHE | 24.19% | $227.19M | 0.35% |
IWM | 23.83% | $80.66B | 0.19% |
VTWO | 23.73% | $13.16B | 0.1% |
PRFZ | 23.24% | $2.75B | 0.39% |
EDOC | 23.07% | $43.10M | 0.68% |
GSSC | 22.91% | $553.05M | 0.2% |
FBT | 22.88% | $1.19B | 0.56% |
PSC | 22.66% | $743.92M | 0.38% |
PINK | 22.64% | $164.95M | 0.5% |